-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
November 2022 marks the 22nd Global Lung Cancer Awareness Month
.
Has lung cancer become chronic? Fang Jian, member of the Chemotherapy Professional Committee of the Chinese Anti-Cancer Association, vice president of the Beijing Cancer Prevention and Treatment Research Association, chairman of the Lung Cancer Subcommittee, and chief physician of the Second Department of Thoracic Oncology of Peking University Cancer Hospital, said that with the progress of lung cancer diagnosis and treatment, clinical treatment plans have gradually become refined, and lung cancer has gradually entered the era of
"chronic disease".
At present, many efforts are still needed to improve drug access, allow patients to receive better treatment, promote the gradual deepening of the management of chronic lung cancer, and truly achieve the goal of
lung cancer becoming a chronic disease.
.
Has lung cancer become chronic? Fang Jian, member of the Chemotherapy Professional Committee of the Chinese Anti-Cancer Association, vice president of the Beijing Cancer Prevention and Treatment Research Association, chairman of the Lung Cancer Subcommittee, and chief physician of the Second Department of Thoracic Oncology of Peking University Cancer Hospital, said that with the progress of lung cancer diagnosis and treatment, clinical treatment plans have gradually become refined, and lung cancer has gradually entered the era of
"chronic disease".
At present, many efforts are still needed to improve drug access, allow patients to receive better treatment, promote the gradual deepening of the management of chronic lung cancer, and truly achieve the goal of
lung cancer becoming a chronic disease.
Fang Jian said that lung cancer is the largest cancer in China, accounting for more than one-third of the total number of lung cancer patients in the world, and lung cancer has always occupied the first
place in China's incidence and mortality.
At present, the common treatment methods of lung cancer include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
, especially the emergence of targeted therapy has created a new era of precision treatment of lung cancer, more and more lung cancer patients have benefited from it, and the overall survival and quality of life of lung cancer patients have been continuously improved
.
place in China's incidence and mortality.
At present, the common treatment methods of lung cancer include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
, especially the emergence of targeted therapy has created a new era of precision treatment of lung cancer, more and more lung cancer patients have benefited from it, and the overall survival and quality of life of lung cancer patients have been continuously improved
.
According to reports, according to the different histopathological characteristics, lung cancer is divided into non-small cell lung cancer and small cell lung cancer, accounting for about 80% to 85% and 15% respectively
.
.
Fang Jian said that compared with common targets, the probability of occurrence of rare target mutations in lung cancer is low and difficult to be found in the clinic, and even if it is diagnosed, there is a lack of corresponding targeted drugs for treatment
.
However, due to the large population base of lung cancer in China, the number of lung cancer patients with this rare mutation cannot be ignored
.
These patients urgently need more innovative and effective therapeutic drugs to prolong survival and improve quality of life
.
However, the current incidence of rare targets for lung cancer is low, and there is a lack of corresponding high-quality therapeutic drugs
.
.
However, due to the large population base of lung cancer in China, the number of lung cancer patients with this rare mutation cannot be ignored
.
These patients urgently need more innovative and effective therapeutic drugs to prolong survival and improve quality of life
.
However, the current incidence of rare targets for lung cancer is low, and there is a lack of corresponding high-quality therapeutic drugs
.
However, he said that the marketing and wide application of immunosuppressants in recent years have brought new treatment options
to patients with rare targets.
At present, a number of MET inhibitors have been approved for marketing in the world, and China has also achieved good results
in the research and development of targeted drugs for late NSCLC with METex14 mutation.
Taking China's first MET targeted innovative drug as an example, its emergence not only fills the gap of domestic MET inhibitors, but also frees some patients with advanced lung cancer from the dilemma of "no drug available", brings more choices and hopes for their survival, achieves breakthrough treatment progress in clinical practice, and is expected to become the first lung cancer targeted innovative drug
representing China to the world.
to patients with rare targets.
At present, a number of MET inhibitors have been approved for marketing in the world, and China has also achieved good results
in the research and development of targeted drugs for late NSCLC with METex14 mutation.
Taking China's first MET targeted innovative drug as an example, its emergence not only fills the gap of domestic MET inhibitors, but also frees some patients with advanced lung cancer from the dilemma of "no drug available", brings more choices and hopes for their survival, achieves breakthrough treatment progress in clinical practice, and is expected to become the first lung cancer targeted innovative drug
representing China to the world.
He said that for patients, through precise targeted therapy, the treatment options of MET rare mutation lung cancer patients are further enriched, so that patients can get rid of the dilemma of no drug and obtain higher treatment accessibility and better quality
of life.
For doctors, based on the current situation that the disease is difficult to diagnose and the few available drugs, providing clinicians with new problem-solving ideas and standardized diagnosis and treatment weapons will improve the diagnosis and treatment level and efficacy
of lung cancer in China.
of life.
For doctors, based on the current situation that the disease is difficult to diagnose and the few available drugs, providing clinicians with new problem-solving ideas and standardized diagnosis and treatment weapons will improve the diagnosis and treatment level and efficacy
of lung cancer in China.
Fang Jian pointed out that with the development of targeted drugs, immunotherapy drugs, and multidisciplinary comprehensive treatment, the overall survival rate of patients has also been improved
through precise individualized treatment.
According to clinical data, in the past, the general five-year survival rate of advanced lung cancer was only 1% to 5%, but now after individualized precision treatment, the five-year survival rate of advanced lung cancer patients can reach 20% to 30%.
Patients with lung cancer in the early and middle stages also have a chance to
be cured after active treatment.
through precise individualized treatment.
According to clinical data, in the past, the general five-year survival rate of advanced lung cancer was only 1% to 5%, but now after individualized precision treatment, the five-year survival rate of advanced lung cancer patients can reach 20% to 30%.
Patients with lung cancer in the early and middle stages also have a chance to
be cured after active treatment.
So, has lung cancer become a truly chronic disease? In Fang Jian's view, lung cancer has gradually entered the era of "chronic disease", but so far, the vast majority of advanced lung cancer has not
been reached.
If continuous drug innovation and continuous optimization of treatment strategies bring hope for the long-term survival of lung cancer, then improving drug access is the key to
achieving this goal.
"Compared with ten or twenty years ago, today's level of scientific research and drug development is unimaginable at that time
.
We believe that the future of lung cancer treatment and drug development is also unimaginable today, and at that time may truly achieve the goal and ideal of making lung cancer a chronic disease, so that patients can receive better treatment and improve the overall cancer survival rate
in China.
(End)
been reached.
If continuous drug innovation and continuous optimization of treatment strategies bring hope for the long-term survival of lung cancer, then improving drug access is the key to
achieving this goal.
"Compared with ten or twenty years ago, today's level of scientific research and drug development is unimaginable at that time
.
We believe that the future of lung cancer treatment and drug development is also unimaginable today, and at that time may truly achieve the goal and ideal of making lung cancer a chronic disease, so that patients can receive better treatment and improve the overall cancer survival rate
in China.
(End)
